, Overview and Essential Characteristics The IU Simon Cancer Center is an NCI-designated Cancer Center that is dedicated to cancer research, education, and patient care for the citizens of Indiana and beyond. Since our last review, the IUSCC has substantially increased the depth and breadth of our science and cancer relevant research as evidenced by over a 38% increase in NCI funding (Direct Costs), a 176% increase in our multi-PI grants while attracting over 30 new investigators in cancer research to our institution. We are the home to the country's first pathway-driven SPORE that focuses on pediatric tumors and the birthplace to three active cancer consortia, including one that links researchers from North America and sub-Saharan Africa. The IUSCC is composed of two basic programs, Hematopoiesis and Hematologic Malignancies (HHM) and Tumor Microenvironment and Metastasis (TMM), and two translational programs, Experimental and Developmental Therapeutics (EDT) and Cancer Prevention and Control (CPC). We define our catchment area as the entire state of Indiana as patients come from each of the 92 counties and 89% of the counties have at least one patient entered on clinical trials. Our community outreach and engagement activities have focused on the urban and rural populations of Indiana with the diseases with the highest mortality in the state, (i.e. lung, breast and gastrointestinal cancers) as well as behavioral risk factors, which adversely impact screening and prevention (e.g. tobacco and HPV vaccinations). We focus on developing novel approaches for screening, treatment and symptom science using precision medicine and expanding work in bioinformatics and medical informatics to address the increasing complexity of understanding the genomic and clinical data. We embrace the vision of increasing the research workforce in Indiana and globally through education from Teens-to-Tenure and the integration of clinical and translational research in our strategic plan. This strategic plan, which has its underpinnings with education and impact to our catchment area, is composed of four pillars that are foundational to the IUSCC. These pillars include: 1) Biology to Bedside Research; 2); Precision Medicine; 3) Prevention, Early Detection and Population Health: Local-Global Approaches; and 4) Health Care Disparities, Survivorship, and Symptom Science.

Public Health Relevance

, Overview and Essential Characteristics The Indiana University Melvin and Bren Simon Cancer Center is an NCI-designated Cancer Center whose mission is to conduct outstanding translational research, to provide excellence in education and to deliver high quality, patient centered care with the goal to eliminate cancer's burden in Indiana and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082709-21
Application #
9987536
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
1999-09-22
Project End
2024-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Reese, Michael J; Knapp, Deborah W; Anderson, Kimberly M et al. (2018) In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs. PLoS One 13:e0203517
Singh, Pratibha; Fukuda, Seiji; Liu, Liqiong et al. (2018) Survivin Is Required for Mouse and Human Bone Marrow Mesenchymal Stromal Cell Function. Stem Cells 36:123-129
Olivos 3rd, David J; Perrien, Daniel S; Hooker, Adam et al. (2018) The proto-oncogene function of Mdm2 in bone. J Cell Biochem 119:8830-8840
Shiue, Kevin; Cerra-Franco, Alberto; Shapiro, Ronald et al. (2018) Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol 13:1549-1559
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Pin, Fabrizio; Barreto, Rafael; Kitase, Yukiko et al. (2018) Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle 9:685-700
Robertson, Michael J; Stamatkin, Christopher W; Pelloso, David et al. (2018) A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. J Immunother 41:151-157
Huang, Xinxin; Guo, Bin; Liu, Sheng et al. (2018) Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment. Nat Commun 9:2741
Serratore, Nina D; Baker, Kortany M; Macadlo, Lauren A et al. (2018) A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics 208:1037-1055
Hoggatt, Jonathan; Singh, Pratibha; Tate, Tiffany A et al. (2018) Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. Cell 172:191-204.e10

Showing the most recent 10 out of 256 publications